SCHEMBL302140

SCHEMBL302140

N#Cc1cc(S(=O)(=O)N(Cc2ccccc2)c2cccc(N3CCNC3=O)c2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.47
HTR1A P08908 1/20 0.47
HTR2A P28223 1/20 0.47
HTR7 P34969 1/20 0.47
DRD3 P35462 1/20 0.47
HTR6 P50406 1/20 0.47
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NR3C1 P04150 3/20 0.39
PGR P06401 2/20 0.39
POLB P06746 1/20 0.39
CNR2 P34972 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
ESR1 P03372 1/20 0.37
NR1H2 P55055 1/20 0.36
MAPT P10636 2/20 0.36
TRPM8 Q7Z2W7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL302086 0.93 CNR2 (0.43) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL1965541 0.84 KMT2A (0.52) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL303078 0.80 CNR2 (0.55) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL22273557 0.75 MEN1 (0.54) MEN1KMT2AL3MBTL1NR3C1PGR
SCHEMBL302217 0.73 HTR2C (0.47) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL303519 0.73 HTR2C (0.45) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL29563853 0.72 NR3C1 (0.53) MEN1KMT2AL3MBTL1NR3C1PGR
SCHEMBL22273575 0.72 NR3C1 (0.53) MEN1KMT2AL3MBTL1NR3C1PGR
SCHEMBL3276020 0.70 HTR6 (0.42) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL303069 0.69 HTR2C (0.55) HTR2CHTR1AHTR2AHTR7DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP claimed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US claimed
JP-2012500835-A 2012-01-12 JP claimed
EP-2334637-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-06-22 EP claimed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP disclosed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
EP-2334637-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-06-22 EP disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 HTR2C 3430/4885HTR1A 1235/4885HTR2A 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.